The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis

Aims/objective To describe the effectiveness of continuous subcutaneous insulin infusion (CSII) in patients with symptomatic diabetic gastroparesis and unstable glycaemic control. Methods Data from 26 patients with symptomatic diabetic gastroparesis and unstable glycaemic control using multiple-dose insulin (MDI) regimens, and subsequently managed with CSII, were analysed. Results Following initiation of CSII, the median length of inpatient bed days associated with hospital admissions related to gastroparesis and glycaemic instability was reduced from 8.5 (range 0–144) days patient −1 year −1 prior to CSII to 0 (range 0–15) days patient −1 year −1 . The median HbA 1c reduction with CSII was 1.8% (22 mmol/mol; p